Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
EDISON EQUITY RESEARCH: ANGLE: ADR UPDATE - THIRD CLINICAL APPLICATION EMERGESAngle has announced results from a metastatic breast cancer research study carried out by its KOL partner...
EDISON EQUITY RESEARCH: ANGLE - CELLS FOR PRECISION MEDICINEAngle has transformed into a pure-play diagnostics business. Parsortix, its proprietary cell separation system, can be used to capture...
ANGLE plc's Parsortix System Harvests CTCS In 100% Of Prostate Cancer Patients Barts study demonstrates Parsortix harvested cells are clinically relevant in prostate cancer PR Newswire GUILDFORD...
ANGLE plc appoints Jim Reuben Scientific Adviser PR Newswire GUILDFORD, England, June 3, 2015 GUILDFORD, England, June 3, 2015 /PRNewswire/ -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY), the specialist...
ANGLE plc Updates Results on Ovarian Cancer Study PR Newswire GUILDFORD, United Kingdom, April 21, 2015 GUILDFORD, United Kingdom, April 21, 2015 /PRNewswire/ -- ANGLE plc (AIM:AGL OTCQX:ANPCY...
Results From The Sidney Kimmel Cancer Center At Thomas Jefferson University PR Newswire GUILDFORD, England, April 20, 2015 GUILDFORD, England, April 20, 2015 /PRNewswire/ -- ANGLE plc (AIM:AGL...
S&P Capital IQ Initiates Coverage on ANGLE Plc in S&P Capital IQ Factual Stock Reports PR Newswire NEW YORK, March 16, 2015 NEW YORK, March 16, 2015 /PRNewswire/ -- S&P Capital IQ...
ANGLE plc ("Angle" or "the Company") Collaboration With MD Anderson Cancer Center On Colorectal Cancer PR Newswire GUILDFORD, England, Feb. 16, 2015 GUILDFORD, England, Feb...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.35 | 1.35 | 1.35 | 754 | 1.35 | CS |
| 12 | 0.6138 | 83.3740831296 | 0.7362 | 1.52 | 0.7362 | 963 | 1.15044762 | CS |
| 26 | -0.87 | -39.1891891892 | 2.22 | 2.44 | 0.7362 | 1393 | 1.4173319 | CS |
| 52 | -0.82 | -37.7880184332 | 2.17 | 3.35 | 0.7362 | 1437 | 1.97256344 | CS |
| 156 | -13.43 | -90.8660351827 | 14.78 | 21 | 0.7362 | 1207 | 2.44042124 | CS |
| 260 | -7.85 | -85.3260869565 | 9.2 | 21 | 0.7362 | 992 | 3.54414301 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
